CureVac NV
NASDAQ:CVAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CureVac NV
Total Equity
CureVac NV
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CureVac NV
NASDAQ:CVAC
|
Total Equity
€696.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Total Equity
€19.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Total Equity
€484.1m
|
CAGR 3-Years
31%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Total Equity
€509.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
|
Heidelberg Pharma AG
XETRA:HPHA
|
Total Equity
€30.9m
|
CAGR 3-Years
66%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
Total Equity
€461.8m
|
CAGR 3-Years
102%
|
CAGR 5-Years
57%
|
CAGR 10-Years
43%
|
|
CureVac NV
Glance View
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.
See Also
What is CureVac NV's Total Equity?
Total Equity
696.6m
EUR
Based on the financial report for Dec 31, 2024, CureVac NV's Total Equity amounts to 696.6m EUR.
What is CureVac NV's Total Equity growth rate?
Total Equity CAGR 3Y
0%
Over the last year, the Total Equity growth was 35%.
